• Supernus Pharmaceuticals requested Nasdaq delisting following completion of its merger on November 2, 2026.
• Trading suspension was requested effective before the November 2, 2026, market open; common stock will no longer trade on any national securities exchange.
• Nasdaq was asked to file Form 25 to delist and deregister the common stock under Section 12(b) of the Exchange Act.
• Following Form 25 effectiveness, it plans to file Form 15 to deregister common stock and suspend Exchange Act reporting obligations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Supernus Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-121103), on November 02, 2026, and is solely responsible for the information contained therein.